FDA Oncology Announcements

Topoisomerase I inhibitor × Clear all

3 Announcements

FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma

Trial: NAPOLI 3
Drugs: Onivyde (irinotecan liposome) · Topoisomerase I inhibitor, oxaliplatin · Platinum agent
Condition: Gastrointestinal

Irinotecan liposome injection

Drug: ONIVYDE (irinotecan liposome) · Topoisomerase I inhibitor
Condition: Gastrointestinal

FDA approves topotecan hydrochloride (hycamtin) in combination with cisplatin for the treatment of Stage IVB recurrent or persistent carcinoma of the cervix

Drugs: Hycamtin (topotecan hydrochloride) · Topoisomerase I inhibitor, cisplatin · Platinum agent
Condition: Gynecologic